Fig. 4 | Cellular & Molecular Immunology

Fig. 4

From: Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

Fig. 4

SARS-CoV-2 infection in the lungs at 6 days post challenge in rhesus macaques vaccinated with one or two dose(s) of CoVLP, CoVLP + CpG, or CoVLP + AS03. Equivalent (Eq.) viral copy (VC) of subgenomic E gene RNA in (A) nasal swabs and (B) subgenomic N gene RNA in the BALF were measured by real-time PCR. The dotted line represents the limit of detection of the method. Samples below the limit of detection were assigned a value of 250 Eq.VC/mL for graphical representation. (C) SARS-CoV-2-infected cells identified by immunohistochemistry and quantified. Individual data and the median (line) are represented

Back to article page